Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H23NO.ClH |
Molecular Weight | 317.853 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=LPRLDRXGWKXRMQ-UHFFFAOYSA-N
InChI=1S/C19H23NO.ClH/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17;/h2-11,18-19H,12-15H2,1H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H23NO |
Molecular Weight | 281.392 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1912125 |
4.1 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Belfene Approved UseUnknown |
|||
Primary | Belfene Approved UseUnknown |
|||
Primary | Belfene Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4156058/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENYLPYRALINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
[Antimycobacterial antihistaminics]. | 1989 Aug |
|
Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives. | 2008 Dec 15 |
|
Application of dummy molecularly imprinted solid-phase extraction in the analysis of cyproheptadine in bovine urine. | 2009 May |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1912125
Brain tissue was obtained at autopsy on 18 Japanese patients with chronic schizophrenia. The brain tissues were weighed, homogenized and centrifuged. The specific 3H-mepyramine binding to the brain tissues reached equilibrium values within 20 min after incubation at 25°C. Inhibition of the specific component of the 3H-mepyramine binding by Diphenylpyraline was then studied. The H1 antagonist diphenylpyraline (Ki=4.1nM) was potent competitors for the specific binding of 3H-mepyramine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:37 GMT 2023
by
admin
on
Fri Dec 15 15:13:37 GMT 2023
|
Record UNII |
G9FU7F1E87
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
61825
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
31508
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
SUB01778MIG
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
66063
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
DTXSID7047772
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
C65424
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
G9FU7F1E87
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
m4640
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
203155
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1492
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
DBSALT000807
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
205-049-3
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
100000087536
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
132-18-3
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
C009871
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |